¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ Àν¶¸° ½ÃÀå
Human Recombinant Insulin
»óǰÄÚµå : 1798913
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 189 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ Àν¶¸° ½ÃÀåÀº 2030³â±îÁö 310¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 276¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ Àν¶¸° ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 1.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 310¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ´Ü½Ã°£ ÀÛ¿ëÇü Àΰ£ Àν¶¸°Àº CAGR 1.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 176¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß°£ ÀÛ¿ëÇü Àΰ£ Àν¶¸° ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 75¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Àΰ£ ÀçÁ¶ÇÕ Àν¶¸° ½ÃÀåÀº 2024³â¿¡ 75¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 57¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 3.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 0.8%¿Í 1.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ Àν¶¸° ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö À¯ÀüÀÚ ÀçÁ¶ÇÕ Àν¶¸°ÀÌ ¿À´Ã³¯ ´ç´¢º´ °ü¸®ÀÇ Áß½ÉÀÌ µÇ´Â°¡?

È÷Æ®¸®ÄÞºñ³×ÀÌÆ® Àν¶¸°Àº Àϰü¼º, ¸é¿ª¿ø¼º °¨¼Ò, È®Àå °¡´ÉÇÑ »ý»êÀ¸·Î ÀÎÇØ ´ç´¢º´ °ü¸®ÀÇ ÁÖ¿ä Ä¡·áÁ¦·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ DNA ±â¼úÀ» »ç¿ëÇÏ¿© Á¦Á¶µÈ ÀÌ Àν¶¸°Àº µ¿¹° À¯·¡ÀÇ ±âÁ¸ Àν¶¸°À» ´ëüÇÏ¿© Àΰ£ÀÇ »ý¸®Àû ±â´É°úÀÇ ÀûÇÕ¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. Á¦1Çü ¹× 2Çü ´ç´¢º´ ȯÀÚ´Â Ç÷´ç Á¶ÀýÀ» À§ÇØ Àν¶¸°ÀÌ ÇÊ¿äÇϹǷΠÀ¯ÀüÀÚ ÀçÁ¶ÇÕ Á¦Á¦´Â Áúº´À» Á¶ÀýÇϰí ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ±âÃÊ Àν¶¸° Á¦Á¦ ¹× À¯¿¬ÇÑ Åõ¿©¹ýÀÇ º¸±ÞÀ¸·Î ¼ÓÈ¿¼º ¹× Áö¼ÓÇü À¯ÀüÀÚ ÀçÁ¶ÇÕ Àν¶¸° À¯»çü¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¼¼°è¿¡¼­ ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø °¡´ÉÇÑ ¾àµ¿ÇÐ ¹× ºÎÀÛ¿ëÀ» °¨¼Ò½ÃŰ´Â Àν¶¸° Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. È÷Æ®¸®ÄÞºñ³×ÀÌÆ® Àν¶¸°Àº º´¿ø¿¡¼­ÀÇ ±Þ¼º±â Ä¡·áºÎÅÍ Àå±âÀûÀÎ ¿Ü·¡ »ç¿ë±îÁö ȯÀÚ±º°ú Ä¡·á ȯ°æ Àü¹Ý¿¡ °ÉÃÄ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¾Æ³¯·Î±× Á¦Á¦¿Í Àΰ£Çü ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Á¦ÀÇ °³¹ß·Î °í¼Òµæ±¹ ½ÃÀå°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼­ Á¢±ÙÀÌ ¿ëÀÌÇØÁ³½À´Ï´Ù. ´ç´¢º´ Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ °³¼±µÇ°í Á¶±â Áø´ÜÀ²ÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àν¶¸° ¿ä¹ý¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼øÀÀµµ°¡ Áö¼ÓÀûÀ¸·Î Çâ»óµÇ¾î Á¦Ç°ÀÇ º¸±ÞÀÌ ´õ¿í È®´ëµÉ °ÍÀÔ´Ï´Ù.

Á¦Çü Çõ½Å°ú Àü´Þ ±â¼úÀº ¾î¶»°Ô ¹ßÀüÇϰí Àִ°¡?

Á¦Çü °³¼±À¸·Î À¯ÀüÀÚ ÀçÁ¶ÇÕ Àν¶¸° Á¦Á¦ÀÇ Ä¡·á ÇÁ·ÎÆÄÀϰú »ç¿ë¼ºÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÇöÀç 1ÀÏ 1ȸ ¶Ç´Â ÁÖ 1ȸ Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÈ Àå±âÁö¼ÓÇü Á¦Á¦´Â ¼øÀÀµµ¸¦ ³ôÀ̰í ÁÖ»ç Ƚ¼ö¸¦ ÁÙÀÏ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¼ÓÈ¿¼º Àν¶¸° Á¦Á¦´Â ´õ »¡¸® ÀÛ¿ëÇϰí, ´õ ªÀº ÀÛ¿ë ½Ã°£À¸·Î ½ÄÈÄ Ç÷´ç Á¶ÀýÀÌ °¡´ÉÇϵµ·Ï °³¼±µÈ Á¦Ç°ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿É¼ÇÀ» ÅëÇØ ȯÀÚ´Â ÀÚ½ÅÀÇ ¶óÀÌÇÁ½ºÅ¸ÀÏ, ½Ä½À°ü, Ȱµ¿ ¼öÁØ¿¡ µû¶ó ¸ÂÃãÈ­µÈ ¿ä¹ýÀ» ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ¿ª½Ã È¿´É°ú ¾ÈÀü¼ºÀ» ¶³¾î¶ß¸®Áö ¾ÊÀ¸¸é¼­µµ ¿À¸®Áö³Î Àν¶¸° Á¦Á¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â Àú·ÅÇÑ ´ë¾ÈÀ» Á¦½ÃÇϸç Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

Á¦ÇüÀÇ º¯È­¿Í ´õºÒ¾î Àü´Þ ½Ã½ºÅÛµµ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº Áö¿ª¿¡¼­ ¹Ì¸® ä¿öÁø Àν¶¸° Ææ, īƮ¸®Áö ½Ã½ºÅÛ, Àç»ç¿ë °¡´ÉÇÑ ÀåÄ¡°¡ ±âÁ¸ÀÇ ¹ÙÀ̾˰ú ÁÖ»ç±â¸¦ ´ëüÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Åõ¾à ÃßÀû ¹× ºí·çÅõ½º ¿¬°á ±â´ÉÀ» °®Ãá ½º¸¶Æ® Àν¶¸° ÆæÀº ÅëÇÕ ´ç´¢º´ °ü¸® Ç÷§ÆûÀÇ ÀϺΰ¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº »ç¿ëÀÚ°¡ Àν¶¸° »ç¿ë·®À» ÃßÀûÇϰí, Åõ¿© ´©¶ô ¹× Áߺ¹ Åõ¿©¸¦ ÇÇÇÔÀ¸·Î½á ´õ ³ªÀº Ç÷´ç Á¶ÀýÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ÀåÄ¡¿Í ȣȯµÇ´Â Àν¶¸° ÆßÇÁµµ ¹ßÀüÇϰí ÀÖÀ¸¸ç, ÀϺΠȯÀÚ±º¿¡¼­´Â Æó¼â ·çÇÁ ½Ã½ºÅÛÀ» ÅëÇØ °ÅÀÇ ÀÚµ¿È­µÈ Àν¶¸° Åõ¿©°¡ °¡´ÉÇØÁ³½À´Ï´Ù.

È÷Æ®¸®ÄÞºñ³×ÀÌÆ® Àν¶¸°¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡Àå ±ÞÁõÇϰí ÀÖ´Â °÷Àº?

È÷Æ®¸®ÄÞºñ³×ÀÌ¼Ç Àν¶¸°¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡Àå ¸¹ÀÌ Áõ°¡ÇÏ´Â °÷Àº µµ½ÃÈ­, ½Ä½À°ü º¯È­, ÁÂ½Ä »ýȰ½À°üÀ¸·Î ÀÎÇØ ´ç´¢º´ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ½ÃÀåÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ±¹°¡µéÀº °øÁߺ¸°Ç ÇÁ·Î±×·¥, ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦¾à»ç¿ÍÀÇ Á¦ÈÞ, Çʼö ÀǾàǰ ¸®½ºÆ®¿¡ Àν¶¸° Á¦Á¦ Ãß°¡ µîÀ» ÅëÇØ Àν¶¸° Á¦Á¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÎ½Ä °³¼± Ä·ÆäÀΰú °ËÁø Ȱµ¿À¸·Î Áø´ÜÀÌ °³¼±µÇ¾î Àå±â Àν¶¸° Ä¡·á¸¦ ¹Þ´Â ȯÀÚ±ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÅÈï ½ÃÀå¿¡¼­´Â Àα¸ °í·ÉÈ­¿Í Àν¶¸°À» ÇÊ¿ä·Î ÇÏ´Â 2Çü ´ç´¢º´ Áõ°¡°¡ ¼ö¿ä¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº °¡Ä¡ ±â¹Ý ÀÇ·á·Î ÀüȯÇϰí ÀÖÀ¸¸ç, ´õ ³ªÀº ¼øÀÀµµ¿Í °á°ú¸¦ Áö¿øÇÏ´Â ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í µðÁöÅÐ Àü´Þ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. º´¿ø, Áø·á¼Ò, ÀçÅÃÄ¡·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ÇコÄÉ¾î ¼ö¿äµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ °í·ÉÀÚ Áý´ÜÀÇ ÇÕº´Áõ °ü¸®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× ¹Î°£ ÁöºÒ ±â°üÀº Àν¶¸°ÀÇ °æÁ¦¼º°ú °¡¿ë¼ºÀ» º¸ÀåÇϱâ À§ÇØ °¡°Ý Çù»ó°ú À¯Åë ¸ðµ¨¿¡¼­ Àû±ØÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

È÷Æ®¸®ÄÞºñ³×ÀÌÆ® Àν¶¸° ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

È÷Æ®¸®ÄÞºñ³×ÀÌÆ® Àν¶¸° ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ´ç´¢º´ À¯º´·ü Áõ°¡, Àν¶¸° Á¦Á¦ ±â¼ú Çâ»ó, ÷´Ü Àü´Þ ½Ã½ºÅÛ Ã¤Åà Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¾Æ³¯·Î±× ¼³°èÀÇ ±â¼úÀû Áøº¸´Â Áö¼ÓÇü, ÃʼÓÈ¿¼º, Àúº¯·®Çü Àν¶¸° Á¦Á¦ÀÇ °³¹ßÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Ä¡·áÀÇ Á¤È®¼º°ú ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ã۰í, ´õ ³ªÀº Ç÷´ç Á¶ÀýÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. µðÁöÅÐ Ææ, ¿þ¾î·¯ºí ÆßÇÁ, ¸ð¹ÙÀÏ ¿¬µ¿ ÃßÀû ÅøÀº Àν¶¸° Åõ¿©¿Í ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖÀ¸¸ç, ƯÈ÷ ÀþÀº ¿¬·ÉÃþ°ú ±â¼ú ¹®ÇØ·ÂÀÌ ³ôÀº ȯÀÚ Áý´Ü¿¡¼­ Àν¶¸° Åõ¿©¿Í ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

°øÁß º¸°Ç ÇÁ·Î±×·¥, ½Ã¼³ ÇÁ·Î¹ÙÀÌ´õ, ÀçÅÃÄ¡·áÀÇ ÃÖÁ¾ ¿ëµµ È®´ë·Î ÀÎÇØ ¼ö¿äÀÇ Àϰü¼ºÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀå¿¡¼­´Â ÇöÁö »ý»êÀ» °­È­ÇÏ°í ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÇ º¸±ÞÀ» ÃËÁøÇϱâ À§ÇÑ ³ë·ÂÀ¸·Î °ø±Þ¸Á ¾ÈÁ¤¼º°ú °¡°ÝÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ÇコÄÉ¾î ½Ã½ºÅÛ°úÀÇ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ³óÃÌÁö¿ªÀ̳ª ÀÇ·á¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡µµ Æø³ÐÀº À¯ÅëÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â °¡Ä¡ ±â¹Ý Ä¡·á¿Í ÅëÇÕ ´ç´¢º´ Ä¡·á Ç÷§ÆûÀ¸·ÎÀÇ ÀüȯÀÌ Àν¶¸°ÀÇ Àå±âÀûÀÎ »ç¿ëÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÀÇ·á Çõ½Å, Åõ¿© È¿À²¼º, ȯÀÚ Á¢±Ù¼ºÀ» Á¶Á¤Çϰí È÷Æ®¸®ÄÞºñ³×ÀÌÆ® Àν¶¸° ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

ÀǾàǰ(´Ü½Ã°£ ÀÛ¿ëÇü Àΰ£ Àν¶¸° Á¦Á¦, Áß°£ ÀÛ¿ëÇü Àΰ£ Àν¶¸° Á¦Á¦, ÇÁ¸®¹Í½ºÇü Àΰ£ Àν¶¸° Á¦Á¦)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Human Recombinant Insulin Market to Reach US$31.0 Billion by 2030

The global market for Human Recombinant Insulin estimated at US$27.6 Billion in the year 2024, is expected to reach US$31.0 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Short-acting Human Insulin, one of the segments analyzed in the report, is expected to record a 1.5% CAGR and reach US$17.6 Billion by the end of the analysis period. Growth in the Intermediate-acting Human Insulin segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.5 Billion While China is Forecast to Grow at 3.6% CAGR

The Human Recombinant Insulin market in the U.S. is estimated at US$7.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 3.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Human Recombinant Insulin Market - Key Trends & Drivers Summarized

Why Is Recombinant Insulin Central to Diabetes Management Today?

Human recombinant insulin has become the primary treatment for diabetes management due to its consistency, reduced immunogenicity, and scalable production. Derived using recombinant DNA technology, it replaces older forms of animal-derived insulin, offering improved compatibility with human physiology. Patients with type 1 and type 2 diabetes require insulin to regulate blood glucose levels, making recombinant formulations critical for disease control and prevention of complications. The widespread adoption of basal-bolus regimens and flexible dosing has further increased reliance on rapid-acting and long-acting recombinant insulin analogs.

Rising diabetes prevalence globally has increased demand for insulin products that provide predictable pharmacokinetics and reduced adverse reactions. Human recombinant insulin offers a reliable solution across patient populations and care settings, from hospital-based acute care to long-term outpatient use. Availability of both analog and human biosimilar variants has supported accessibility in both high-income and developing markets. As awareness of diabetes care improves and early diagnosis rates increase, patient adherence to insulin therapy continues to rise, further boosting product uptake.

How Are Formulation Innovations and Delivery Technologies Advancing?

Formulation improvements are enhancing the therapeutic profile and usability of recombinant insulin products. Long-acting formulations are now designed for once-daily or even weekly use, helping improve compliance and reduce injection frequency. Rapid-acting analogs are being refined to deliver better post-meal glucose control with faster onset and shorter duration of action. These options allow patients to personalize regimens based on lifestyle, diet, and activity level. Biosimilars are also gaining traction, offering lower-cost alternatives to branded insulins without compromising efficacy or safety.

Delivery systems are evolving in parallel with formulation changes. Prefilled insulin pens, cartridge systems, and reusable devices have replaced traditional vials and syringes in many regions. Smart insulin pens with digital dose tracking and Bluetooth connectivity are becoming part of integrated diabetes management platforms. These systems enable better glucose control by helping users track insulin usage and avoid missed or duplicate doses. Insulin pumps compatible with continuous glucose monitoring devices are also advancing, with closed-loop systems providing near-automated insulin delivery in select patient groups.

Where Is Demand for Human Recombinant Insulin Rising Most Rapidly?

Demand for human recombinant insulin is growing fastest in emerging markets where diabetes prevalence is rising due to urbanization, dietary changes, and sedentary lifestyles. Countries in Asia Pacific, Latin America, and the Middle East are scaling up insulin access through public health programs, partnerships with biosimilar manufacturers, and increased inclusion of insulin in essential medicine lists. Awareness campaigns and screening initiatives are improving diagnosis and expanding the patient base for long-term insulin therapy.

In developed markets, aging populations and increasing incidence of insulin-requiring type 2 diabetes are sustaining demand. Health systems are shifting towards value-based care, encouraging adoption of biosimilars and digital delivery systems that support better adherence and outcomes. Institutional demand from hospitals, clinics, and home healthcare providers is also rising, particularly in response to comorbidity management in elderly populations. Government and private payers are playing an active role in price negotiations and distribution models to ensure insulin affordability and availability.

What Is Driving Growth in the Human Recombinant Insulin Market?

Growth in the human recombinant insulin market is driven by several factors including rising global diabetes incidence, improvements in insulin formulation technologies, and increased adoption of advanced delivery systems. Technological advancements in analog design are supporting the development of long-acting, ultra-fast, and low-variability insulin products. These innovations improve treatment precision and patient comfort while enabling better glycemic control. Digital pens, wearable pumps, and mobile-linked tracking tools are enhancing insulin delivery and adherence, particularly in younger and tech-literate patient populations.

End-use expansion across public health programs, institutional providers, and home-based care is increasing demand consistency. In emerging markets, efforts to strengthen local manufacturing and promote biosimilar uptake are improving supply chain stability and affordability. Partnerships between pharmaceutical companies and healthcare systems are enabling broad distribution, even in rural or underserved regions. In high-income countries, the shift towards value-based treatment and integrated diabetes care platforms is reinforcing long-term insulin use. Together, these developments are driving sustainable growth in the human recombinant insulin market by aligning medical innovation, delivery efficiency, and patient access.

SCOPE OF STUDY:

The report analyzes the Human Recombinant Insulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Short-acting Human Insulin, Intermediate-acting Human Insulin, Premixed Human Insulin)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â